Advertisement
Canada markets closed
  • S&P/TSX

    22,290.62
    +31.15 (+0.14%)
     
  • S&P 500

    5,187.70
    +6.96 (+0.13%)
     
  • DOW

    38,884.26
    +31.99 (+0.08%)
     
  • CAD/USD

    0.7286
    -0.0035 (-0.48%)
     
  • CRUDE OIL

    78.37
    -0.11 (-0.14%)
     
  • Bitcoin CAD

    86,531.83
    -531.81 (-0.61%)
     
  • CMC Crypto 200

    1,308.29
    -56.83 (-4.16%)
     
  • GOLD FUTURES

    2,322.50
    -8.70 (-0.37%)
     
  • RUSSELL 2000

    2,064.65
    +3.97 (+0.19%)
     
  • 10-Yr Bond

    4.4630
    -0.0260 (-0.58%)
     
  • NASDAQ futures

    18,197.75
    +2.25 (+0.01%)
     
  • VOLATILITY

    13.23
    -0.26 (-1.93%)
     
  • FTSE

    8,313.67
    +100.18 (+1.22%)
     
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • CAD/EUR

    0.6771
    -0.0021 (-0.31%)
     

Why Intellia Therapeutics Stock Jumped This Week

Why Intellia Therapeutics Stock Jumped This Week

Shares of the gene-editing pioneer Intellia Therapeutics (NASDAQ: NTLA) rose by 17.5% through the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. There are currently eight medications approved by the FDA to prevent and/or treat HAE attacks. NTLA-2002, however, could be the first genetic medicine for this indication (depending on its ongoing clinical trials).